Article Sidebar
Published:
Feb 9, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Effects of a combination of moxapride and fluoxetine on gastrointestinal function in patients with functional dyspepsia-associated anxiety
Abstract
Purpose: To study the effects of a combination of mosapride and fluoxetine in patients with functional dyspepsia-associated anxiety, and its impact on gastrointestinal function.
Methods: One hundred (100) cases of patients with anxiety linked to functional dyspepsia, who were admitted to the Department of Gastroenterology of Shengjing Hospital, China Medical University from January 2019 to May 2020, were retrospectively selected and randomly divided into control and study groups (n = 50). The control group patients received moxapride monotherapy, while those in the study group were given moxapride in combination with fluoxetine. The two groups of patients were compared daily for 4 days with respect to treatment effectiveness, Mental Status Scale in Non-psychiatric Settings (MSSNS), Barthel Index (BI), Self-Rating Anxiety Scale (SAS), Self-Rating Depression Scale (SDS), time intervals for flatulence and defecation, as well as bowel sounds, and levels of gastric juice and cholecystokinin.
Results: Treatment effectiveness, BI index, number of intestinal rumblings, and level of gastrin in the study group were significantly higher than those in control group after 1, 2, 3 and 4 days of treatment (p < 0.05). Moreover, scores for SAS, SDS and MSSNS, as well as time intervals for flatulence and defecation, and level cholecystokinin in the study group were significantly lower than those in control group (p < 0.05).
Conclusion: The combination of mosapride and fluoxetine has high application benefit for patients with anxiety associated with functional dyspepsia when compared with the control.
